We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,755.00
Bid: 4,750.00
Ask: 4,754.00
Change: 101.00 (2.17%)
Spread: 4.00 (0.084%)
Open: 4,678.00
High: 4,767.00
Low: 4,649.00
Prev. Close: 4,654.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition update

26 Oct 2018 07:00

RNS Number : 2558F
Croda International PLC
26 October 2018
 

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(B) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER ALIA, SAVE WITH THE CONSENT OF THE PANEL ON TAKEOVERS AND MERGERS, REQUIRES A PARTY TO AN OFFER TO PROMPTLY MAKE AN ANNOUNCEMENT SHOULD IT DECIDE TO TAKE A COURSE OF ACTION DIFFERENT FROM ITS STATED INTENTIONS DURING THE PERIOD OF 12 MONTHS FROM THE END OF THE OFFER PERIOD EXPLAINING ITS REASONS FOR SO DOING.

 

For immediate release

26 October 2018

CRODA EUROPE LIMITED

Update on strategy and reasons for changes to stated post-offer intentions with regard to Plant Impact plc

Croda Europe Limited ("Croda Europe") announces that further to the completion of its recommended cash offer for the entire issued and to be issued ordinary share capital of Plant Impact plc ("Plant Impact")("the Offer"), which was effected by way of a scheme of arrangement under Part 26 of the Companies Act 2006 on 28 March 2018 (the "Acquisition"), its board of directors (the "Croda Europe Board") has taken certain necessary courses of action which differ from the statements of intent made pursuant to Rules 2.7(c)(iv) and 24.2 of the Code (the "Stated Intentions"), as set out in its announcement of 16 February 2018 and the scheme document published on 26 February 2018 (together, the "Offer Documentation").

Reasons for changes to the Stated Intentions

As set out in the Offer Documentation, it was the Croda Europe Board's intention, following completion of the Offer, to undertake an exercise to evaluate the market positioning and strategy of Plant Impact and how best to integrate Plant Impact, its activities and employees into the wider Croda group. This evaluation exercise is now complete and its findings have necessitated certain changes to the original Stated Intentions in order to best utilise Plant Impact's technology, skills and wider employee base and position the business effectively to address its end markets in a sustainable way.

These internal changes will have no impact on existing business, customer service levels or Croda's fundamental rationale for the acquisition. Overall the integration programme has been positive, with the majority of Plant Impact's employees being successfully integrated into the wider Croda group, which employs more than 4,300 people globally.

Updates to Stated Intentions in respect of Plant Impact's Brazilian activities

Croda has identified a specific need to change Plant Impact's commercial strategy and the route to market in Brazil. As a consequence, it is intended that there will be a reconfiguration of the sales force together with an associated redundancy programme in relation to Plant Impact's agricultural sales team in Brazil. Following this programme, Plant Impact's business in Brazil will operate from local offices of the Croda group and the lease on the Plant Impact office in Brazil will not be required and therefore will not be renewed. The net impact of Croda's integration plans on Plant Impact Brazil is likely to be a reduction of nine roles.

As part of its broader global activities, Croda remains positive about the prospects for Plant Impact's business and is continuing to invest resources, time and capital in several areas such as research and development activity aimed at sustainable long-term growth.

Enquiries:

Croda Europe

Tel: +44 (0) 140 586 0551

Conleth Campbell

 

 

GCA Altium, financial adviser to Croda Europe

 

Tel: +44 (0) 845 505 4300

Phil Adams

 

Paul Lines

 

 

GCA Altium, which is authorised and regulated in the UK by the Financial Conduct Authority, is acting exclusively for Croda Europe and no one else in connection with the matters set out in this announcement. In connection with such matters, GCA Altium will not regard any other person as its client, nor will it be responsible to any other person for providing the protections afforded to clients of GCA Altium or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQPGGPAUUPRPUA
Date   Source Headline
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.